



The European Agency for the Evaluation of Medicinal Products
Pre-authorisation Evaluation of Medicines for Human Use

London, 1 December 2003
EMEA/CPMP/3257/03/en/Final

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
SUMMARY INFORMATION ON REFERRAL OPINION FOLLOWING ARBITRATION
PURSUANT TO ARTICLE 30 OF COUNCIL DIRECTIVE 2001/83/EC FOR
Calcichew-D3 and associated names

International NonProprietary Name (INN): Calcium 500 mg / cholecalciferol 10 µg

BACKGROUND INFORMATION

Cholecalciferol (vit D₃), undergoes a biotransformation into 1,25 dihydroxycholecalciferol, a main active metabolite of vitamine D, which is necessary to promote the intestinal absorption of calcium. Calcium is essential for a number of physiological functions and particularly bone mineralization.

Medicinal products containing cholecalciferol and/or carbonate calcium have been nationally authorised in EU Member States, resulting in different Summaries of Product Characteristics based on individual national decisions.

Nycomed Pharma AS presented to the EMEA a referral under Article 30 of Directive 2001/83/EC, in order to harmonise the national SPCs of the medicinal product Calcichew-D₃ and associated names and additionally to harmonise the pharmaceutical documentation. A dossier in CTD format and a proposal for a harmonised SPC were submitted by the MAH on 20 September 2002. The referral procedure started on 27 September 2002.

The CPMP having considered the Rapporteur and the Co-Rapporteur assessment reports, and scientific discussion within the Committee was of the opinion that the benefit/risk ratio of calcium carbonate is considered to be favourable. The CPMP issued a positive opinion, on 26 June 2003, recommending the harmonisation of the SPC for Calcichew-D₃ and associated names for the following agreed therapeutic indications: prevention and treatment of vitamine D and calcium deficiency; vitamin D and calcium supplement as an adjunct to specific osteoporosis treatment of patients who are at risk of vitamin D and calcium deficiency.

An overall summary of the scientific evaluation is provided in Annex II together with the amended summary of product characteristics in Annex III.

A Decision was issued by the European Commission on 1 December 2003.

Public

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 13
E-mail: mail@emea.eu.int <http://www.emea.eu.int>

©EMEA 2004 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged